A Planned Trial to Evaluate the Safety and Efficacy of Tafenoquine + Atovaquone/Azithromycin in Hospitalized Patients With Babesiosis

J Infect Dis. 2024 Jul 25;230(1):271-272. doi: 10.1093/infdis/jiae193.
No abstract available

Publication types

  • Letter
  • Editorial
  • Comment

MeSH terms

  • Aminoquinolines
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / therapeutic use
  • Atovaquone* / adverse effects
  • Atovaquone* / therapeutic use
  • Azithromycin* / administration & dosage
  • Azithromycin* / adverse effects
  • Azithromycin* / therapeutic use
  • Babesiosis* / drug therapy
  • Drug Therapy, Combination
  • Fluorenes / administration & dosage
  • Fluorenes / adverse effects
  • Fluorenes / therapeutic use
  • Hospitalization
  • Humans
  • Treatment Outcome

Substances

  • Atovaquone
  • tafenoquine
  • Azithromycin
  • Fluorenes
  • Anti-Bacterial Agents
  • Aminoquinolines

Grants and funding